Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.

CONCLUSIONS: Subcutaneously administered glucagon produces a stable pharmacokinetic and pharmacodynamic response at lower doses than the usual rescue dose and across a range of hypo- to hyperglycaemic blood glucose levels. This confirms the use of small glucagon doses in the artificial pancreas to correct and prevent hypoglycaemia. PMID: 26343550 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26343550?dopt=Abstract

Source: Diabetes Metab - September 7, 2015 Category: Endocrinology Authors: Blauw H, Wendl I, DeVries JH, Heise T, Jax T Tags: Diabetes Obes Metab Source Type: research

More News: Diabetes | Diabetes Type 1 | Endocrinology | Pancreas | Study